Showing posts with label Virginia Board of Pharmacy. Show all posts
Showing posts with label Virginia Board of Pharmacy. Show all posts

Saturday, March 30, 2013

Virginia Board of Veterinary Medicine Use of Compounded Drugs in Vetererinary Practice Adopted Februrary 7, 2013-includes office use


Virginia Board of Veterinary Medicine
Use of Compounded Drugs in Veterinary Practice
Applicable Laws

§ 54.1-3401. Definitions.

As used in this chapter, unless the context requires a different meaning:
"Compounding" means the combining of two or more ingredients to fabricate such ingredients into a single preparation and includes the mixing, assembling, packaging, or labeling of a drug or device (i) by a pharmacist, or within a permitted pharmacy, pursuant to a valid prescription issued for a medicinal or therapeutic purpose in the context of a bona fide practitioner-patient-pharmacist relationship, or in expectation of receiving a valid prescription based on observed prescribing patterns; (ii) by or for a practitioner of medicine, osteopathy, podiatry, dentistry, or veterinary medicine as an incident to his administering or dispensing, if authorized to dispense, a controlled substance in the course of his professional practice; or (iii) for the purpose of, or as incident to, research, teaching, or chemical analysis and not for sale or for dispensing. The mixing, diluting, or reconstituting of a manufacturer's product drugs for the purpose of administration to a patient, when performed by a practitioner of medicine or osteopathy licensed under Chapter 29 (§ 54.1-2900 et seq.), a person supervised by such practitioner pursuant to subdivision A 6 or A 19 of § 54.1-2901, or a person supervised by such practitioner or a licensed nurse practitioner or physician assistant pursuant to subdivision A 4 of § 54.1-2901 shall not be considered compounding.

 

§ 54.1-3410.2. Compounding; pharmacists' authority to compound under certain conditions; labeling and record maintenance requirements.

A. A pharmacist may engage in compounding of drug products when the dispensing of such compounded products is (i) pursuant to valid prescriptions for specific patients and (ii) consistent with the provisions of § 54.1-3303 relating to the issuance of prescriptions and the dispensing of drugs.
Pharmacists shall label all compounded drug products that are dispensed pursuant to a prescription in accordance with this chapter and the Board's [Pharmacy] regulations, and shall include on the labeling an appropriate beyond-use date as determined by the pharmacist in compliance with USP-NF standards for pharmacy compounding.
B. A pharmacist may also engage in compounding of drug products in anticipation of receipt of prescriptions based on a routine, regularly observed prescribing pattern.
Pharmacists shall label all products compounded prior to dispensing with (i) the name and strength of the compounded medication or a list of the active ingredients and strengths; (ii) the pharmacy's assigned control number that corresponds with the compounding record; (iii) an appropriate beyond-use date as determined by the pharmacist in compliance with USP-NF standards for pharmacy compounding; and (iv) the quantity.
C. In accordance with the conditions set forth in subsections A and B, pharmacists shall not distribute compounded drug products for subsequent distribution or sale to other persons or to commercial entities, including distribution to pharmacies or other entities under common ownership or control with the facility in which such compounding takes place.
A pharmacist may, however, deliver compounded products dispensed pursuant to valid prescriptions to alternate delivery locations pursuant to § 54.1-3420.2.
A pharmacist may also provide compounded products to practitioners of medicine, osteopathy, podiatry, dentistry, or veterinary medicine to administer to their patients in the course of their professional practice, either personally or under their direct and immediate supervision.
Pharmacists shall label all compounded products distributed to practitioners for administration to their patients with (i) the statement "For Administering in Prescriber Practice Location Only"; (ii) the name and strength of the compounded medication or list of the active ingredients and strengths; (iii) the facility's control number; (iv) an appropriate beyond-use date as determined by the pharmacist in compliance with USP-NF standards for pharmacy compounding; and (v) quantity.
E. Pharmacists shall ensure compliance with USP-NF standards for both sterile and non-sterile compounding.
J. Practitioners who may lawfully compound drugs for administering or dispensing to their own patients pursuant to §§ 54.1-3301, 54.1-3304, and 54.1-3304.1 shall comply with all provisions of this section and the relevant Board regulations.

Guidance
Q: May a veterinarian prescribe a compounded drug product?
A: A Virginia licensed veterinarian may prescribe a compounded drug product by preparing a valid prescription pursuant to federal and state laws and regulations for an individual patient with which there exists a valid veterinarian-client-patient relationship. The client may obtain the compounded drug product from a pharmacy of their choice that is properly licensed by the Virginia Board of Pharmacy. The payment arrangements for a prescribed compounded drug product are not under the purview of the Board of Veterinary Medicine. However, a pharmacist must be compliant with the Virginia Board of Pharmacy regulation, 18VAC110-20-390(A), which states “A Pharmacist shall not solicit or foster prescription practice with a prescriber of drugs or any other person providing for rebates, ‘kickbacks,’ fee-splitting, or special charges in exchange for prescription orders unless fully disclosed in writing to the patient and any third party payor.”
Q: May a veterinarian obtain compounded drug products from a pharmacy for administration in their office?
A: Yes, a Virginia licensed veterinarian may obtain compounded drug products from a pharmacy that is properly licensed by the Virginia Board of Pharmacy for administration in the course of their professional practice. Pursuant to Virginia Code § 54.1-3410.2(C) the pharmacist is required to label the compounded drug product with the statement “For Administering in Prescriber Practice Location Only.”
Q: May a veterinarian dispense a compounded drug product?
A: A veterinarian may dispense a compounded drug product if compounded by the veterinarian pursuant to Virginia Code § 54.1-3410.2(J).
Q: May a pharmacy provide compounded drug products to a veterinarian for the veterinarian to dispense to his patients?
A: No, Virginia Code § 54.1-3410.2 prohibits pharmacists from distributing compounded drug products for subsequent distribution or sale to other persons.
Q: What is the penalty for a licensee of the Virginia Board of Veterinary Medicine who is found to be dispensing compounded drug product purchased from a pharmacy?
A: The licensee may be subject to disciplinary action.

source found here:  
  1. 54.1-3410.2. Compounding; pharmacists' authority to compound ...

    https://www.dhp.virginia.gov/vet/guidelines/150-5.doc
    File Format: Microsoft Word - Quick View
    Feb 7, 2013 – Use of Compounded Drugs in Veterinary Practice ... as incident to, research, teaching, or chemical analysis and not for sale or for dispensing

Monday, February 18, 2013

Draft/Unapproved Minutes from Jan. 14, 2013 Meeting of Virginia Board of Pharmacy--Disciplinary action against Christopher K. Currin



VIRGINIA BOARD OF PHARMACY
MINUTES OF TELEPHONE CONFERENCE CALL

Monday, January 14, 2013 Department of Health Professions
Perimeter Center
9960 Mayland Drive, Suite 300
Henrico, Virginia  23233-1463
Orders/Consent Orders referred to in these minutes are available upon request
TIME & PURPOSE: Pursuant to § 54.1-2400(13) of the Code of Virginia, a telephone conference call of the Virginia Board of Pharmacy (“TCC”) was held at 10:25 a.m., on January 14, 2013, to consider the summary restriction of the license of Christopher K. Currin to practice as a pharmacist in the Commonwealth of Virginia.
PRESIDING: David C. Kozera, Chair
MEMBERS PRESENT: R. Crady Adams
Jody H. Allen
Dinny Li
Empsy Munden
Ellen B. Shinaberry
STAFF PRESENT: Caroline D. Juran, Executive Director
Cathy M. Reiniers-Day, Deputy Executive Director
Eusebia L. Joyner, Disciplinary Program Specialist
Mykl Egan, DHP Adjudication Specialist 
Howard Casway, Senior Assistant Attorney General
Wayne T. Halbleib, Senior Assistant Attorney General
Nan Dunaway, DHP Pharmacy Inspector 
Vicki Garrison, DHP Pharmacy Inspector

POLL OF MEMBERS: The Board members were polled as to whether they could have attended a regular meeting at the office in a timely manner for the purpose of hearing evidence in a possible summary suspension case.  The Board members stated that they would not have been able to attend.  
With six (6) members participating and four (4) members unable to participate, it was established that a quorum could not have been convened in a regular meeting to consider this matter.
CHRISTOPHER K. CURRIN
License No. 0202 011727 Wayne T. Halbleib presented a summary of the evidence in this case.

Upon a motion by Ms. Allen and duly seconded by Ms. Shinaberry, the Board voted 6-0, to convene  a closed meeting pursuant to § 2.2-3711(A) (27) of the Code of Virginia (“Code”), for the purpose of deliberation to reach a decision in the matter of Christopher K. Currin.  Additionally, she moved that Caroline Juran, Cathy Reiniers-Day, Eusebia Joyner and Howard Casway attend the closed meeting. 

At approximately, 12:50 p.m., Ms. Juran departed.
 
Reconvene: Having certified that the matters discussed in the preceding closed meeting met the requirements of § 2.2-3712 of the Code, the Board re-convened in open meeting and announced the decision.
Decision: Upon a motion by Ms. Munden and duly seconded by Mr. Adams, the Board unanimously voted 6-0 that, with the evidence presented, the practice as a pharmacist by Christopher K. Currin poses a substantial danger to the public; and therefore, said license to practice pharmacy in the Commonwealth of Virginia be and hereby is Restricted.

Upon a motion by Ms. Allen and seconded by Ms. Shinaberry, the Board voted that a Consent Order for a stay of the restriction with certain terms and conditions be offered to Mr. Currin.
ADJOURN: With all business concluded, the meeting adjourned at 1:10 p.m.
Cathy M. Reiniers-Day
Deputy Executive Director 
Eusebia L. Joyner
Disciplinary Program Specialist
David C. Kozera, Chair
Date


Sunday, December 30, 2012

Saturday, September 8, 2012

Compliance with USP Standards for Media-fill testing is required in Virginia

Compliance with USP Standards for
Compounding
Media-fill testing is required when performing low, medium,
and high-risk level compounding of compounded sterile preparations
 (CSPs). USP35-NF30 states:
Media-Fill Test Procedure – This test or an equivalent
test is performed at least annually by each person
authorized to compound in a low-risk level environment
under conditions that closely simulate the most
challenging or stressful conditions encountered during
compounding of low-risk level CSPs. Once begun,
this test is completed without interruption. Quality
assurance procedures for medium-risk level CSPs
include all those for low-risk level CSPs, as well as
a more challenging media-fill test passed annually
or more frequently. In addition, a media-fill test that
represents high-risk level compounding is performed
semiannually by each person authorized to compound
high-risk level CSPs. 
On June 12, 2012, the Board approved changes to Guidance
Document 110-36. The terms “annually” and “semiannually”
as used in United States Pharmacopeia (USP) Chapters 795 and
797 are defined to mean every 12 months and every six months,
respectively. Records associated with annual and semiannual
requirements shall be maintained for two years from the date
performed. Such records may be maintained in off-site storage
or as an electronic image that provides an exact image of the
document that is clearly legible provided such off-site or electronic
storage is retrievable and made available for inspection or
audit within 48 hours of a request by the Board or an authorized
agent. Board of Pharmacy guidance documents are available at
www.dhp.virginia.gov/Pharmacy/pharmacy_guidelines.htm.